Tirzepatide: the science behind dual-action weight loss

What is tirzepatide?

Tirzepatide is a once-weekly injectable medication and the first of a new class of drugs: a dual GIP and GLP-1 receptor agonist. Developed by Eli Lilly, it's FDA-approved under two brand names — Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management, approved November 2023).

It belongs to the incretin class — medications that mimic the gut hormones your body naturally releases after you eat. Those hormones tell your brain you're full and help regulate blood sugar. Tirzepatide amplifies that signal, which is why appetite and cravings fall.

At Expert Health, tirzepatide is prescribed by a US-licensed provider and compounded by an FDA-regulated pharmacy. Compounded medications are not FDA-approved. See the disclaimer below.

How tirzepatide works

Most weight-loss medications in this category act on a single hormone pathway. Tirzepatide is different: it activates two receptors at once — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are "incretin" hormones that regulate appetite and how your body handles food.

By engaging both pathways, tirzepatide tends to produce stronger appetite reduction than a single-hormone GLP-1 medication alone.

• Quiets appetite — signals fullness to the brain, so you eat less without white-knuckling it.
• Slows gastric emptying — food stays in your stomach longer, so you feel full for longer.
• Reduces cravings — the constant "food noise" tends to fade.
• Improves insulin response — which is why the same molecule is also used to treat type 2 diabetes.

What the clinical research shows

Tirzepatide's weight-loss evidence comes primarily from Eli Lilly's SURMOUNT trial program. The pivotal trial, SURMOUNT-1, was a 72-week study of around 2,500 adults with obesity or overweight (without diabetes), published in The New England Journal of Medicine in 2022.

At the three target doses, participants lost an average of 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) of their body weight, compared with 2.4% on placebo. Up to 96% of those on the higher doses lost at least 5% of their body weight. A later head-to-head trial (SURMOUNT-5) reported roughly 47% greater average weight loss than semaglutide over 72 weeks.

Importantly, these results were achieved alongside a reduced-calorie diet and increased activity, and tirzepatide tends to drive greater fat-mass loss than lean-mass loss. Trial averages are not promises — individual results vary based on dose, adherence, and your biology.

Tirzepatide vs. semaglutide

Both tirzepatide and semaglutide are incretin therapies, but they're not identical. Semaglutide (the molecule in Ozempic and Wegovy) is a GLP-1-only agonist. Tirzepatide adds GIP — the dual-action that, in the SURMOUNT-5 head-to-head trial, produced greater average weight loss.

That doesn't make one universally "better." The right choice depends on your history, how you tolerate the medication, your budget, and how you respond. That's a decision to make with a provider — which is exactly what the free consult is for.

More options

Explore more weight loss solutions

All treatments

GLP-1 Semaglutide as low as $199/mo

Triple agonist Retatrutide as low as $399/mo

See every weight loss treatment Browse all

Who it's for — and who it isn't

Tirzepatide is a medical treatment, not a lifestyle supplement. A provider confirms it's appropriate before prescribing.

Safety & side effects

The most common side effects are gastrointestinal — nausea, diarrhea, constipation, vomiting, and reduced appetite. They tend to be mild to moderate, peak when the dose is increased, and fade over the following 2–4 weeks as your body adjusts. In SURMOUNT-1, nausea was reported by roughly 24–33% of participants, diarrhea 17–23%, constipation 11–17%, and vomiting 6–13% (rates rise with dose).

Most people who experience GI effects continue treatment; relatively few stop because of them. Starting low and titrating slowly — exactly how a provider prescribes it — is the main lever for keeping side effects manageable.

Less common but more serious risks include dehydration from GI effects (which can affect the kidneys), gallbladder problems, and pancreatitis. Tirzepatide also carries a boxed warning for thyroid C-cell tumors, based on rodent studies. This is why provider oversight, screening, and check-ins matter — and why this should never be a gray-market purchase.

How Expert Health prescribes tirzepatide

It starts with a free consult. A US-licensed provider reviews your goals and health history and confirms whether tirzepatide is appropriate for you. If it is, you start at a low dose and titrate up over several weeks — the approach shown to minimize side effects.

Your medication is compounded by an FDA-regulated pharmacy and shipped to your door, and provider check-ins every four weeks keep your dose matched to how you're responding. You're never left to figure it out alone.

Frequently asked questions

Sources

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine, 2022
2. FDA Approves New Medication for Chronic Weight Management (Zepbound) — U.S. Food & Drug Administration, 2023
3. Zepbound (tirzepatide) Prescribing Information — U.S. FDA Label
4. Tirzepatide — StatPearls — NCBI Bookshelf / National Library of Medicine
5. SURMOUNT-1 results announcement — Eli Lilly and Company